CereGate lands oversubscribed Series C for Parkinson's brain-computer interface

What's the deal? Munich-based medtech company CereGateDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed Series C round to advance its brain-computer interface technology. The round is led by an unnamed US medical technology group and includes Budapest-based Impact VenturesDealroom has a profile for this one. Try Dealroom → as a first-time backer, alongside returning investors. CereGate did not disclose the amount, valuation, or ownership stakes.

What's the endgame? Founded in 2019, CereGate builds software that runs on Boston Scientific's deep brain stimulation systems. The technology is designed to treat neurological disorders — initially gait disorders in Parkinson's patients, where existing treatments often fall short.

How it works: Deep brain stimulation sends electrical signals to specific brain regions via implanted electrodes, a procedure already used for Parkinson's and other conditions. CereGate's software aims to expand what those systems can do. Its technology is currently in clinical trials.

Why now? The capital will fund ongoing studies and lay the groundwork for future therapeutic uses. Securing a strategic investor from the medical technology industry signals industry confidence in the approach and could open a path to commercialisation.

The signal: An oversubscribed round — where demand topped the planned target — points to investor appetite for neurotechnology that builds on established hardware rather than starting from scratch. By layering software onto Boston Scientific's existing platform, CereGate offers a lower-risk route into a market long dominated by hardware players.

Read more: startbase.com

Image credit: CereGate